Leukemia (2008), 1–6
& 2008 Nature Publishing Group All rights reserved 0887-6924/08 $30.00
www.nature.com/leu
KEYNOTE ADDRESS
The role of vertebral augmentation in multiple myeloma: International Myeloma
Working Group Consensus Statement
MA Hussein1, FD Vrionis2, R Allison3, J Berenson4, S Berven5, E Erdem6, S Giralt7, S Jagannath8, RA Kyle9, S LeGrand10,
R Pflugmacher11, N Raje12, SV Rajkumar9, L Randall13, D Roodman14, D Siegel15, R Vescio16, J Zonder17 and BGM Durie16
on behalf of the International Myeloma Working Group18
1
Department of Hematologic Malignancies, H Lee Moffitt Cancer Center, Tampa, FL, USA; 2Department of Neuro-Oncology, H Lee
Moffitt Cancer Center, Tampa, FL, USA; 3Department of Radiation Oncology, Brody School of Medicine at ECU, Greenville, NC,
USA; 4Department of Hematology/Medical Oncology, Institute for Myeloma & Bone Cancer Research, Los Angeles, CA, USA;
5
Department of Orthopaedic Surgery, University of California, San Francisco, CA, USA; 6Division of Radiology, Section of
Interventional Neuroradiology, University of Arkansas for Medical Sciences, Little Rock, AR, USA; ; 7Stem Cell Transplantation &
Cellular Therapy Department, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 8Department of Medical
Oncology/Internal Medicine, St Vincent’s Comprehensive Cancer Center, New York, NY, USA; 9Department of Laboratory Medicine
and Pathology, Mayo Clinic, MN, USA; 10Department of Medical Oncology/Internal Medicine, Cleveland Clinic Foundation,
Cleveland, OH, USA; 11Department of Musculature, Charité der Humboldt Universitàt, Berlin, Germany; 12Department of Medical
Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; 13Department of Orthopaedics, Huntsman
Cancer Institute, Salt Lake City, UT, USA; ; 14Department of Hematology/Oncology, University of Pittsburgh School of Medicine,
Pittsburgh, PA, USA; 15Department of Medical Oncology, Hackensack Cancer Center, Hackensack, NJ, USA; 16Department of
Hematology/Oncology, Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA, USA and 17Department of Medicine, Division of
Hematology-Oncology, Karmanos Cancer Center, Wayne State University School of Medicine, Detroit, MI, USA
Leukemia advance online publication, 29 May 2008;
doi:10.1038/leu.2008.127
Introduction
There are approximately 20 000 new patients diagnosed with
myeloma in the United States each year.1 With the availability
of better treatments and resultant improved survival, there are
currently close to 100 000 patients living with myeloma in the
United States. Similar incidence and prevalence rates exist
throughout Europe.2 Of these patients, the spine is affected by
osteolytic and/or osteopenic bone disease in 70%.3 Myeloma is
the commonest primary cancer affecting the spine. Painful
vertebral compression fractures (VCFs) affect approximately
30% of myeloma patients. As myeloma patients live longer, it is
especially relevant to provide the best available treatment for
pain and reduce disabilities that can result from VCFs.4
The focus of this summary is to assess the role of minimally
invasive percutaneous injection of polymethyl methacrylate
(PMMA), first developed as ‘vertebroplasty’ in France in the late
1980s. Considerable experience accrued, especially in Europe,
with the use of vertebroplasty as treatment for painful VCFs. The
fractured bone fragments are stabilized and strengthened by
PMMA and pain is substantially improved. A more recent
modification of vertebroplasty is percutaneous balloon kyphoplasty whereby inflation of a balloon prior to PMMA injection
Correspondence: Dr BGM Durie, Aptium Oncology Inc., Cedars-Sinai
Outpatient Cancer Center, 8201 Beverly Boulevard, Los Angeles, CA
90048, USA.
E-mail: bdurie@aptiumoncology.com or
Dr MA Hussein, H Lee Moffitt Cancer & Research Institute 12902
Magnolia Drive, SRB4, Tampa, FL 33612, USA.
Email: mohamad.hussein@moffitt.org
18
See Appendix for members of the International Myeloma Working
Group
Received 18 February 2008; revised 2 April 2008; accepted 28 April
2008
can restore vertebral height and reduce kyphotic deformity in
addition to stabilizing the fractured vertebral body.
The first prospective trial evaluating the role of balloon
kyphoplasty in multiple myeloma showed that over 80% of
the treated patients experienced significant pain control.5
In addition, there was an overall 30% height restoration with
improvement of 60–70% of height restoration when the
procedure was performed for fractures less than 6 months
old.5 The procedure was also noted to be effective and safe in
other malignancies.6 In another study of 20 multiple myeloma
patients (48 levels) treated with balloon kyphoplasty, significant
pain improvement as judged by visual analogue scale occurred
within the first year of follow-up.7 About 80% of patients with
initial kyphotic deformity had post-operative kyphosis correction of approximately 61, with only minimal loss of height after
1 year (B1.81). The overall data related to both vertebroplasty
and balloon kyphoplasty are addressed in a number of
publications.5,8–20
In considering the potential benefit of PMMA injection, it is
necessary to be aware of the biomechanics of pathologic spine
fractures (Figure 1). With the occurrence of a VCF, the center of
gravity moves forward. Because of the large bending moment
created, the anterior spine, especially in the regions adjacent to
the VCF, must resist larger compressive stresses. The posterior
muscles and ligaments are additionally stressed, which can be
an obvious source of pain. Early intervention is a way to reduce
the risk of a ‘domino effect’ with increased forward movement
of the center of gravity, additional compressive stresses and
possible further VCFs. The consequences of progressively
altered vertebral mechanics and the kyphosis-related VCFs in
myeloma patients can be substantial as summarized in Table 1.
Obviously, the safety of vertebral augmentation is an
important consideration. The potential complications of vertebral
augmentation are summarized in Table 2. A literature review
meta-analysis of procedure-related complications for balloon
kyphoplasty and vertebroplasty indicates that complications
such as extravasation of PMMA are less with balloon kyphoplasty.21 It should be noted that asymptomatic extravasation of
The role of vertebral augmentation in multiple myeloma
MA Hussein et al
2
Figure 1 Movement of center of gravity (CG) forward with vertebral
compression fracture.
Table 1
Consequences of VCF-related kyphosis
Compression of abdominal contents
K Anorexia, weight loss
Decreased lung capacity
K Limited exercise tolerance/physical activity
Anterior loading of spine (Figure 1)
K Subsequent fractures
K Increasing kyphosis and deformity
Abbreviation: VCF, vertebral compression fracture.
Table 2
K
K
K
K
K
K
Potential complications of vertebral augmentation
Extravasation of PMMA cementa
J Local effects
J Systemic effects including pulmonary
Cord compression (spinal cord)
Radiculopathy (foramina)
Pneumothorax
Retroperitoneal hematoma
Infection: local/systemic
Abbreviation: PMMA, polymethyl methacrylate.
See text for discussion.
a
Table 3
Outcomes with balloon kyphoplasty at H Lee Moffitt
Cancer Centera
K
K
K
K
K
41 patients; 62 kyphoplasties
13% PMMA extravasation
1 case of pneumothorax; resolved
95% partial or substantial pain relief
All patients discharged within 23 h (i.e. o 1 day)
Abbreviation: PMMA, polymethyl methacrylate.
a
Data published under Vrionis et al.21
PMMA occurs in about 7% balloon kyphoplasty versus 19.7%
vertebroplasty but rarely leads to clinical complications.22 As an
example, the single center experience at Moffitt Cancer Center
Leukemia
gives a realistic expectation as to outcomes in a center
specializing in myeloma care (Table 3). The presence of any
plasmacytoma tissue between the PMMA and the fractured
cortical bone can lead to suboptimal improvement in stabilization and any subsequent pain relief from any form of vertebral
augmentation.9 Active awareness of potential complications and
careful patient selection are obviously crucial.
The role of vertebral augmentation in the treatment of
myeloma of the spine is still evolving. The impact of VCFs
upon quality of life and survival is illustrated by results of a large
study in women aged X65 years. In this study of a total of 9575
women aged 65 years or older, 1915 of the women (20.0%)
were diagnosed as having VCF secondary to osteoporosis. The
fractures were not only associated with increased morbidity, but
also with increased mortality.23 The increased mortality was
particularly from pulmonary complications.23 Moreover, patient
mortality increased with greater numbers of vertebral fractures,
from 19 per 1000 woman-years in women with no fractures to
44 per 1000 woman-years in those with five or more fractures
(Po0.001).
These data accentuate the need for management guidelines
for VCFs. Formal guidelines on the use of vertebral augmentation for myeloma in the spine are missing. The purpose of this
paper is to review the evidence regarding the role of vertebral
augmentation in the spine and to provide a consensus statement
on the role of vertebral augmentation for the management of
myeloma affecting the spine. Those aspects of therapy were
reviewed, discussed and considered by the International
Myeloma Working Group and a special advisory board
convened at the time of the XI International Myeloma Workshop
KOS Greece on 29 June 2007.
The following is the consensus statement from the International
Myeloma Working Group:
1. Indications for vertebral augmentation: The indications are
summarized in Table 4. These indications apply, provided
contraindications are not present as summarized in Table 5.
If severe pain is present, the advisory board reached a
consensus that it is very reasonable to proceed with
immediate vertebral augmentation. A major advantage is
the rapid pain relief especially compared with alternative
analgesic strategies summarized in Table 6. Early augmentation also proactively reduces the risk of the vicious cycle of
further VCFs as described above as well as providing the
maximum chance of restoring height and correcting angular
deformity. Early augmentation also does not preclude
additional or subsequent use of any of the alternative strategies
such as those summarized in Table 6. In the absence of severe
pain, augmentation is a proactive measure to preserve
structural integrity. When there is severe bone destruction
and in anticipation of potential long patient survival, this
secondary indication is very much a viable option to
maximize quality of life by preventing potential VCFs.
2. Identification of patients suitable for vertebral augmentation:
The four major components of the recommended baseline
evaluation are summarized in Table 7. Obviously, one must
be certain that the pain is emanating from the collapsed or
damaged vertebra(e). In addition to X-ray, which most
patients will have undergone to diagnose the problem, more
detailed evaluation with magnetic resonance imaging
(including STIR (Short T1 Inversion Recovery) images) is
essential particularly to determine the presence or absence of
spinal cord compression and/or edema. Also, the potential
for retropulsion and/or direct leakage of PMMA can be
The role of vertebral augmentation in multiple myeloma
MA Hussein et al
3
Table 4
a
Indications for vertebral augmentation
Primary: severe pain present (pain 47/10 on VAS)
K Collapse of one or more vertebra (VCF)
K Bone destruction (osteolytic/osteopenic) with high risk of
collapse of one or more vertebra
Secondary: severe pain absent (pain p7/10 on VAS)
K Significant loss of height and/or structural integrity or stability
Abbreviations: VAS, visual analogue scale; VCF, vertebral compression
fractures.
a
Provided no contraindications (Table 5).
Table 5
Contraindications to vertebral augmentation
Absolute
K
K
K
K
K
K
K
K
K
Relative
Contraindications to general
or local anesthesia
Pregnancy
Bleeding disorder
Infection at the site
K
Lesions above T3
K
K
Pain unrelated to vertebral
collapse
Cord compression
Presence of overt instability
Severe cardiopulmonary
insufficiency
Allergy to procedure-related
drugs/contrast
K
Osteoblastic metastases
Patient o40 years of age
Technically not feasible
(vertebra plana)
Fractures with obstructing
plasmacytoma(ta)
Retropulsed bone
K
K
Table 6
Alternatives for pain therapy
Options
Discussion
PMMA vertebral
augmentation
Radiation therapy
K
Rapid pain relief
K
K
Simple procedure
Pain relief has slower onset and less
complete
Reduces tumor mass swelling and may
eliminate plasmacytoma(ta) locally
Destroys bone marrow stem cells locally
Can be fast acting
K
Systemic antimyeloma therapy
K
K
K
Bisphosphonates
K
K
K
K
K
Analgesics
K
K
May or may not relieve severe local pain
related to bone fragment movement
Does not correct structural integrity
Can give rapid pain relief
May or may not relieve pain from bone
fragments
Gives systemic benefit
Generally very safe
Can be rapid acting and effective
Efficacy relative to augmentation awaits
the results of CAFE trial (Table 8).
Abbreviation: PMMA, polymethyl methacrylate.
assessed. Computed tomography scanning in addition may
be helpful especially if some combined surgical procedure
plus PMMA injection procedure is being considered. It is
helpful to know to what extent systemic antimyeloma
therapy will be required and assess absolute or relative
contraindications as summarized in Table 5.
Table 7
Identification of patients suitable for vertebral augmentation
1 Careful pain assessment to determine source/severity of pain.
2 MRI is essential to document the anatomy and assess spinal cord
edema/compression
3 Assessment of myeloma disease status and potential anti-myeloma
treatment needs
4 Assessment of other pain therapy options (Table 6)
Abbreviation: MRI, magnetic resonance imaging.
3. Timing for the vertebral augmentation: Early intervention is
currently being investigated in the CAFE (Cancer Fracture
Evaluation) trial in which immediate and delayed vertebral
augmentation are being contrasted and compared. The group
reviewed available data and clinical experience available
now and agreed to the following:
Immediate vertebral augmentation is a treatment option
for acute VCF with severe pain or VCF at high risk for
progressive deformity. Excellent short- and long-term
results have been achieved in this setting;
For patients with lesser pain and/or vertebral damage, a
trial of analgesic therapy with supportive measures
including bisphosphonates and/or systemic therapy is
generally recommended. The appropriate duration of this
type of therapeutic trial relates to the severity of the pain
and potential reversibility with systemic measures. In
general, augmentation can be considered as soon as
feasible especially if pain worsens and/or persists and/or
to prevent further vertebral collapse. Early intervention is
especially important if stabilizing the spinal structure and/
or restoring the height are critical. Excellent results have
been achieved in these settings. Results of the ongoing
randomized CAFÉ trial evaluating pain relief and quality of
life with immediate versus delayed balloon kyphoplasty
are eagerly awaited;
If pain persists at the site of VCF, there is no upper time
limit beyond which augmentation cannot be considered.
However, earlier intervention is preferred to achieve
maximal stabilization and/or correction of deformities.
4. Number of levels to be considered for treatment:
Multiple augmentation procedures may be necessary and
appropriate. In general, three to four vertebrae per
intervention is considered reasonable and feasible during
a single procedure (if required). As many as 16 augmentations have been performed on an individual myeloma
patient in separate sessions or stages.
Vertebral augmentation for adjacent or suspect vertebrae
without fracture may be necessary. Such augmentations
can be considered when there is a fracture with kyphosis in
the thoracolumbar region because the stress due to the
deformity in this region is very high. It is particularly
common to consider the performance of an additional
augmentation procedure in a vertebra when it is located
between two fractured vertebrae such as T11 and L1
requiring treatment for T12 to avoid post-procedure T12
collapse.
5. The highest level of augmentation to be performed was
briefly discussed. It was decided that experienced operators
can perform vertebral augmentation to levels as high as the
cervical area and that this can be effective and safe. For
practical purposes, T3–L5 is the range that can be performed
safely by the percutaneous route.
Leukemia
The role of vertebral augmentation in multiple myeloma
MA Hussein et al
4
6. The method of vertebral augmentation: The risk of
complications, especially the risk of PMMA leakage, is
greater with vertebroplasty. However, it was agreed that both
the utility and the likelihood of clinically significant
complications are very much dependent upon the experience of the operator. It is therefore recommended that the
choice of balloon kyphoplasty versus vertebroplasty be left to
the discretion of the operator and be based upon the goals of
the procedure.
7. Use of vertebral augmentation versus radiation therapy:
Vertebral augmentation is considered the procedure of
choice to improve quality of life for painful VCFs. However,
external beam radiotherapy (EBR) is a valid option that
requires careful consideration. EBR is simple and can be
performed in one session without risks of anesthesia,
bleeding, infections or compromise of vital structures. Local
marrow stem cell damage is most likely minimally different
with 30 Gy of EBR versus the impact of heated PMMA
injected into one to three vertebral bodies. Thus, if discreet
plasmacytomata exist within a vertebra and/or there is a
symptomatic extramedullary mass or impending/overt spinal
cord compression occurs, the use of EBR can be the option of
choice. Systemic antimyeloma therapy is an alternative for
rapid reduction in myeloma tumor burden. In addition,
medical pain therapy can provide helpful relief as necessary.
8. Physical rehabilitation: To maximize the recovery from
augmentation, a physical rehabilitation program is recommended. Ideally, this should be in the form of water aerobics
and thoracolumbar stabilization with an extension directional focus, under the supervision of a physical therapist.
9. Further trials are still required to clarify the role of vertebral
augmentation in a variety of situations including the
following:
prevention of further fractures in asymptomatic patients;
treating asymptomatic fractures; and
treating asymptomatic fractures compromising the spinal
structure or pulmonary capacity
Discussion
This International Myeloma Working Group Consensus Statement is the latest in a series of publications from the working
group as summarized in Table 8. Additional consensus
statements scheduled for 2008 include the role of free lightchain analysis; guidelines for use of Epoetin; the role of imaging;
and a new genetic classification for myeloma.
Vertebral augmentation techniques discussed as part of this
consensus statement can be used for both acute and chronic
fractures. Myeloma patients with mechanical pain, that is pain
that is most significant in the upright position, standing or
walking and significantly decreased in a reclining position,
which anatomically correlates with the area of the fracture, are
most likely to benefit from vertebral augmentation. Other types
or causes of pain (radicular, dysesthetic, discogenic or
degenerative) should be carefully assessed as they can coexist
with pain related to compression fractures and are unlikely to
respond to vertebral augmentation interventions.
Absolute contraindications to augmentation including myelopathy or cauda equine syndrome are listed in Table 5. Relative
contraindications include coagulopathy, neutropenia, allergy to
substances used for the procedure and high anesthetic risks
(Table 5).
Leukemia
Table 8
ments
International Myeloma Working Group Consensus State-
Article
Reference
Criteria for classification of
monoclonal gammopathies
Myeloma Management
Guidelines
International Staging System
(ISS) for myeloma
International Uniform Response
Criteria for Multiple Myeloma
Use of Bisphosphonates in
Myeloma
Prevention of Thalidomide and
Lenalidomide associated
Thrombosis in Myeloma
Myeloma in Patients Under Age
50
Br J Haematol 2003;
121:749–57
Hematology Journal
2003;4:379–98
JCO 2005; 23(15):1–9
Leukemia 2006 (1–7)
Mayo Clinic Proceedings
2007; 85:516–22
Leukemia 2008; 22:414–23
Blood, April 2008; 111(8):
4039–47
Currently, there are no specific guidelines or contraindications regarding factors such as kyphosis, retropulsion and caudal
compromise or degree of vertebral body collapse. The issue of
spinal instability and its effect on overall decision making need
to be determined on an individual basis by the treating spine
expert. The unstable spine is at risk of progressive deformity or
impairment of the neural elements. Generally, operative care
with open surgery rather than percutaneous augmentation
techniques is most valuable in the setting of spinal instability.
In addition, the number of fractures that can be treated at each
intervention or stage; the amount of methylmethacrylate to be
injected; the need to treat adjacent or intervening nonfractured
segments; the issue of unilateral or bilateral, transpedicular or
extra-pedicular; open or percutaneous approaches under local
or general anesthesia all need to be determined by the treating
surgeon or radiologist. However, it is recommended that not
more than three or four fractures are treated per stage as the risk
of pulmonary complications increases with the number of
treated fractures. The advisory board delegated the details of this
decision making, related to numbers and methodology, to the
selected operators of the augmentation procedures.
In general, vertebral augmentation is not recommended for
asymptomatic fractures unless there is documented increased
collapse and deformity progression or in the context of an
adjacent or intervening segment. This could be documented by
follow-up radiologic studies performed every 3 months or
sooner if the clinical picture dictates. The role of skeletal
augmentation for sacral or iliac fractures in patients with
myeloma is currently unknown.
As noted above, vertebral augmentation should be considered
as the procedure of choice to improve quality of life for painful
compression spinal fractures in myeloma patients instead of EBR
or placement of intrathecal morphine pumps. In patients with
plasmacytomata in bone or extramedullary plasmacytomata
extending into the epidural space, open surgical decompression
or radiation therapy with or without augmentation may be
appropriate. In patients with a stable spine without fracture or
progressive deformity, radiotherapy should be considered first.
Receiving radiation therapy does not preclude future augmentation. Vertebral augmentation and radiation can be viewed as
complementary, with augmentation restoring anatomy and
radiation ablating symptomatic disease. Augmentation has the
advantage of rapid relief in a single sitting, which should allow
patients requiring radiation to be treated in a more comfortable
state. This is particularly important for individuals undergoing
The role of vertebral augmentation in multiple myeloma
MA Hussein et al
5
radiosurgery where treatment time approaches an hour and
immobility is crucial for accuracy.
In summary, patients with plasmacytomata, extramedullary
masses and cord compromise should be considered for use of
up-front radiotherapy. Vertebral augmentation is a developing
field with current and future trials being necessary to further
define what constitutes an ‘impending fracture’ and establish the
role of pre-emptive augmentation procedures. Having all
options available for multiple myelomas, patients insures
optimal therapeutic intervention to improve both quality of life
and overall survival.
References
1 Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer
Statistics 2007. CA J Clin 2007; 57: 43–66.
2 Boyle P, Ferlay J. Cancer incidence and mortality in Europe 2004.
Ann Oncol 2005; 16: 481–488.
3 Durie BGM, Kyle R, Belch A, Bensinger W, Blade J, Boccadoro M
et al. Myeloma management guidelines: A consensus report from
the scientific advisors of the international myeloma foundation.
Hematol J 2003; 4: 379–398.
4 Durie BGM. New approaches to treatment for multiple myeloma:
durable remission and quality of life as primary goals. Clin
Lymphoma Myeloma 2005; 6: 181–190.
5 Dudeney S, Lieberman IH, Reinhardt MK, Hussein M.
Kyphoplasty in the treatment of osteolytic vertebral compression
fractures as a result of multiple myeloma. J Clin Oncol 2002; 20:
2382–2387.
6 Pflugmacher R, Beth P, Schroeder RJ, Schaser KD, Melcher I.
Balloon kyphoplasty for the treatment of pathological fractures in
the thoracic and lumbar spine caused by metastasis: one year
follow-up. Acta Radiol 2007; 48: 89–95.
7 Pflugmacher R, Kandziora F, Schroeder RJ, Melcher I, Haas NP,
Klostermann CK et al. Percutaneous balloon Kyphoplasty in the
treatment of pathological vertebral body fracture and deformity in
multiple myeloma: a one-year follow-up. Acta Radiol 2006; 47:
369–376.
8 Khanna AJ, Reinhardt MK, Togawa D, Lieberman IH. Functional
outcomes of Kyphoplasty for the treatment of osteoporotic and
osteolytic vertebral compression fractures. Osteoporos Int 2006;
17: 817–826.
9 Gerszten PC, Welch WC. Combined percutaneous transpedicular
tumor debulking and Kyphoplasty for pathological compression
fractures. Technical note. J Neurosurg Spine 2007; 6: 92–95.
Appendix
International Myeloma Working Group:
Ray Alexanian, MD Anderson, Houston, Texas, USA
Kenneth Anderson, DFCI, Boston, Massachusetts, USA
Michael Attal, Purpan Hospital, Toulouse, France
Herve Avet-Loiseau, Institute de Biologie, Nantes, France
Ashraf Badros, University of Maryland, Baltimore, Maryland,
USA
Leif Bergsagel, Mayo Clinic Scottsdale, Scottsdale, Arizona,
USA
Joan Bladé, Hospital Clinica, Barcelona, Spain
Bart Barlogie, MIRT UAMS Little Rock, Arkanas, USA
Regis Batille, Institute de Biologie, Nantes, France
Meral Beksac, Ankara University, Ankara, Turkey
Andrew Belch, Cross Cancer Institute, Alberta, Canada
Bill Bensinger, Fred Hutchinson Cancer Center, Seattle,
Washington, USA
Mario Boccadoro, University of Torino, Torino, Italy
10 Atalay B, Caner H, Gokce C, Altinors N. Kyphoplasty: two years of
experience in a neurosurgery department. Surg Neurol 2005; 64
(S2): 72–76.
11 Crandall D, Slaughter D, Hankins PJ, Moore C, Jerman J. Acute
versus chronic vertebral compression fractures treated with
kyphoplasty: early results. Spine J 2004; 4: 418–424.
12 Fourney DR, Schomer DF, Nader R, Chlan-Fourney J, Siki D, Ahrar
K et al. Percutaneous vertebroplasty and kyphoplasty for painful
vertebral body fractures in cancer patients. J Neurosurg 2003; 98 (1
suppl): 21–30.
13 Gaitanis IA, Hadjipavlou AG, Katonis PG, Tzermiadianos MN,
Pasku DS, Datwardhan AG et al. Balloon kyphoplasty for the
treatment of pathological vertebral compression fractures. Eur
Spine J 2005; 14: 250–260.
14 Gerszten PC, Germanwala A, Burton SA, Welch WC, Ozhasoglu
C, Vogel WJ. Combination of kyphoplasty and spinal radiotherapy:
a new treatment paradigm for pathological fractures. Neurosurg
Focus 2005; 18: e8.
15 Hentschel SJ, Burton AW, Fourney DR, Rhines LD, Mendel E.
Percutaneous vertebroplasty and kyphoplasty performed at a
cancer center: refuting proposed contraindications. J Neurosurg
Spine 2005; 2: 440–446.
16 Kose KC, Cebesoy O, Akan B, Altinel L, Dincer D, Yazar T.
Functional results of vertebral augmentation technique in pathological vertebral fractures of myelomatous patients. J Natl Med
Assoc 2006; 98: 1543–1548.
17 Lane JM, Hong R, Koob J, Kiechle T, Niesvizky R, Pearse R et al.
Kyphoplasty enhances function and structural alignment in multiple myeloma. Clin Orthop 2004; 426: 49–53.
18 Ledlie JT, Renfro MB. Kyphoplasty treatment of vertebral body
compression fractures: 2-year outcomes show sustained benefits.
Spine 2006; 31: 57–64.
19 Lieberman I, Reinhardt MK. Vertebroplasty and kyphoplasty for
osteolytic vertebral collapse. Clin Orthop 2003; 415S: S176–S186.
20 Weber CH, Krotz M, Hoffmann RT, Euler E, Heining S, Pfeifer KJ
et al. CT-guided vertebroplasty and kyphoplasty: comparing
technical success rate and complications in 101 cases. Rofo
2006; 278: 610–617. (Article in German, abstract in English).
21 Vrionis FD, Hamm A, Stanton N, Sullivan M, Obadia M, Muiguel
R. Kyphoplasty for tumor-associated spinal fractures. Tech Reg
Anesth Pain Manag 2005; 9: 35–39.
22 Eck JC, Nachtigall D, Humphreys SC, Hodges SD. Comparison of
vertebroplasty and balloon kyphoplasty for treatment of vertebral
compression fractures: a meta-analysis of the literature. The Spine
Journal 2007, 1–10.
23 Kado DM, Browner WS, Palermo L, Nevitt MC, Genant HK,
Cummings SR. Vertebral fractures and mortality in older women: a
prospective study. Study of Osteoporotic Fractures Research
Group. Arch Intern Med 1999; 159: 1215–1220.
Michele Cavo, Universita di Bologna, Bologna, Italy
Wen Ming Chen, MM Research Center of Beijing, Beijing,
China
Tony Child, Leeds General Hospital, Leeds, United Kingdom
James Chim, Department of Medicine, Queen Mary Hospital,
Hong Kong
Ray Comenzo, Memorial Sloane-Kettering, New York City,
New York, USA
John Crowley, Cancer Research and Biostatistics, Seattle,
Washington, USA
William Dalton, H Lee Moffitt, Tampa, Florida, USA
Faith Davies, Royal Marsden Hospital, London, England
Cármino de Souza, Univeridade de Campinas, Caminas,
Brazil
Michel Delforge, University Hospital Gasthuisberg, Leuven,
Belgium
Meletios Dimipoulous, Alexandra Hospital, Athens,
Greece
Angela Dispenzieri, Mayo Clinic, Rochester, Minnesota, USA
Leukemia
The role of vertebral augmentation in multiple myeloma
MA Hussein et al
6
Hermann Einsele, Universitätsklinik Würzburg, Würzburg,
Germany
Theirry Facon, Centre Hospitalier Regional Universitaire de
Lille, Lille, France
Dorotea Fantl, Socieded Argentinade Hematolgia, Buenos
Aires, Argentina
Jean-Paul Fermand, Hopitaux de Paris, Paris, France
Rafael Fonseca, Mayo Clinic Scottsdale, Scottsdale, Arizona,
USA
Gosta Gahrton, Karolinska Institute for Medicine, Huddinge,
Sweden
Morie Gertz, Mayo Clinic, Rochester, Minnesota, USA
John Gibson, Royal Prince Alfred Hospital, Sydney, Australia
Hartmut Goldschmidt, University Hospital Heidelberg,
Heidelberg, Germany
Philip Greipp, Mayo Clinic, Rochester, Minnesota, USA
Roman Hajek, Brno University, Brno, Czech Republic
Izhar Hardan, Tel Aviv University, Tel Aviv, Israel
Jean-Luc Harousseau, Institute de Biologie, Nantes, France
Hiroyuki Hata, Kumamoto University Hospital, Kumamoto,
Japan
Yutaka Hattori, Keio University School of Medicine, Tokyo,
Japan
Joy Ho, Royal Prince Alfred Hospital, Sydney, Australia
Vania Hungria, Clinica San Germano, Sao Paolo, Brazil
Mohamad Hussein, Cleveland Clinic Taussig Cancer Center,
Cleveland, Ohio, USA
Shinsuke Ida, Nagoya City University Medical School,
Nagoya, Japan
Peter Jacobs, Constantiaberg Medi-Clinic, Plumstead, South
Africa
Sundar Jagannath, St Vincent’s Comprehensive Cancer
Center, New York, New York, USA
Hou Jian, Shanghai Chang Zheng Hospital, Shanghai, China
Douglas Joshua, Royal Prince Alfred Hospital, Sydney,
Australia
Michio Kawano, Yamaguchi University, Ube, Japan
Shaji Kumar, Department of Hematology, Mayo Clinic,
Minnesota, USA
Robert Kyle, Department of Laboratory Med. and Pathology,
Mayo Clinic, Minnesota, USA
Juan Lahuerta, Grupo Espanol di Mieloma, Hospital
Universitario, Madrid, Spain
Jae Hoon Lee, Gachon University Gil Hospital, Incheon,
Korea
Henk Lokhorst, University Medical CenterUtrecht, Utrecht,
The Netherlands
Heinz Ludwig, Wilhelminenspital Der Stat Wien, Vienna,
Austria
Xavier LeLeu, Hospital Huriez, CHRU Lille, France
Angelo Maiolino, Rua fonte da Saudade, Rio de Janeiro,
Brazil
Jayesh Mehta, Northwestern University, Chicago, Illinois,
USA
GianPaolo Merlini, University of Pavia, Pavia, Italy
Philippe Moreau, University Hospital, Nantes, France
Gareth Morgan, Royal Marsden Hospital, London, England
Leukemia
Nikhil Munshi, Diane Farber Cancer Institute, Boston,
Massachusetts, USA
Antonio Palumbo, Cathedra Ematologia, Torino, Italy
Santiago Pavlovsky, Fundaleu, Buenos Aires, Argentina
Ruben Niesvizky, Weill Medical College of Cornell
University, New York, New York, USA
Yana Novis, Hospital Sı́rioLibanês, Bela Vista, Brazil
Amara Nouel, Hospital Rutz y Paez, Bolivar, Venezuela
Raymond Powles, Leukaemia & Myeloma, Wimbledon,
England
Linda Pilarski, University of Alberta, Alberta, Canada
S Vincent Rajkumar, Mayo Clinic, Rochester, Minnesota, USA
Donna Reece, Princess Margaret, Toronto, Canada
Tony Reiman, Cross Cancer Institute, Alberta, Canada
Paul Richardson, Dana Farber Cancer Institute, Boston,
Massachusetts, USA
Angelina Rodriquez Morales, Bonco Metro Politano de
Sangre, Caracas, Venezuela
Orhan Sezer, Department of Hem/Onc, Universitatsklinikum
Charite, Berlin, Germany
John Shaughnessy, M.I.R.T. UAMS, Little Rock, Arkansas,
USA
Kazayuki Shimizu, Nagoya City Midori General Hospital,
Nagoya, Japan
David Siegel, Hackensack, Cancer Center, Hackensack, New
Jersey, USA
Guido Tricot, M.I.R.T. UAMS, Little Rock, Arkansas, USA
Jesus San Miguel, University of Salamanca, Salamanca, Spain
Seema Singhal, Northwestern University, Chicago, Illinois,
USA
Pieter Sonneveld, Erasmus MC, Rotterdam, The Netherlands
Chaim Shustik, McGill, Toronto, Canada
Andrew Spencer, The Alfred Hospital, Melbourne, Australia
Keith Stewart, Mayo Clinic Scottsdale, Scottsdale, Arizona,
USA
Patrizia Tosi, Italian Cooperative Group, Istituto di Ematologia
Seragnoli, Bologna, Italy
Ingemar Turesson, Department of Hematology, Malmo
University, Malmo, Sweden
Brian Van Ness, University of Minnesota, Minneapolis,
Minnesota, USA
Ivan Van Riet, Brussels Vrija University, Brussels, Belgium
Robert Vescio, Cedars-Sinai Outpatient Cancer Center, Los
Angeles, California, USA
David Vesole, St Vincent’s Comprehensive Cancer Center,
New York, New York, USA
Anders Waage, University Hospital, Trondheim, Norway
NSMG
Michael Wang, M.D. Anderson, Houston, Texas, USA
Donna Weber, MD Anderson, Houston, Texas, USA
Jan Westin, University of Lund, Lund, Sweden
Keith Wheatley, University of Birmingham, Birmingham,
United Kingdom
Dina B Yehuda, Department of Hematology, Hadassah
University Hospital, Hadassah, Israel
Jeffrey Zonder, SWOG, Department of Hem/Onc., Karmanos
Cancer Institute, Michigan, USA